Targeting Pancreatic and Ovarian Carcinomas with SGN-75 Antibody-Drug Conjugate

Strategic Insights -

Researchers at Seattle Genetics, Inc. have discovered that the auristatin-based anti-CD70 antibody-drug conjugate SGN-75 can effectively target pancreatic and ovarian carcinomas. CD70, a protein highly expressed in renal carcinomas and non-Hodgkin lymphomas, has been identified as an ideal target for antibody-based therapies. Scientists generated murine monoclonal antibodies specific for CD70 and tested the anti-tumour activity of SGN-75 in various cancer cell lines. The results showed that pancreatic and ovarian tumor cell lines, which express high levels of endogenous or transfected CD70, are sensitive to the anti-tumour activity of SGN-75 in vitro and in vivo.

Key Takeaways:

  • CD70 is an ideal target for antibody-based therapies due to its aberrant high expression in certain cancers and restricted expression in normal tissues.
  • Researchers generated murine monoclonal antibodies specific for CD70 and validated their specificity using western blot analysis and immunohistochemistry.
  • SGN-75, an anti-CD70 antibody-drug conjugate, showed anti-tumour activity in pancreatic and ovarian cell lines in vitro and in vivo.
  • CD70 expression was detected in 25% of pancreatic cancers, 22% of larynx/pharynx cancers, 16% of melanomas, 15% of ovarian cancers, 10% of lung cancers, and 9% of colon cancers.
  • The study provides rationale for expanding the application of SGN-75 for the treatment of multiple CD70 expressing cancers.
  • M.C. Ryan and colleagues published their study in the British Journal of Cancer, highlighting the potential of SGN-75 as a novel therapeutic approach for pancreatic and ovarian carcinomas.

Statistics:

  • 25% - CD70 expression detected in pancreatic cancers
  • 22% - CD70 expression detected in larynx/pharynx cancers
  • 16% - CD70 expression detected in melanomas
  • 15% - CD70 expression detected in ovarian cancers
  • 10% - CD70 expression detected in lung cancers
  • 9% - CD70 expression detected in colon cancers
  • 103 - Volume number of the British Journal of Cancer publication
  • 5 - Issue number of the British Journal of Cancer publication
  • 676-84 - Page numbers of the British Journal of Cancer publication

Sources:

  • Ryan, M.C., et al. "Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75." British Journal of Cancer, vol. 103, no. 5, 2010, pp. 676-84.
  • Biotech Week editors. "Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75." NewsRx.com, 2010.